Analysts are forecasting higher earnings for this medical device company, which has recently announced to acquisitions, boosting its product offerings.
Boston Scientific (BSX)
From Sound Advice
The cloud of uncertainty surrounding the Affordable Care Act (Obamacare) still blankets the healthcare industry.
Our current recommendations in this sector are based on their own individual merits. The decision by Congress to suspend the medical device tax for another two years will benefit Boston Scientific (BSX). The company has been a global medical technology leader for three decades by providing a range of high performance solutions aimed at addressing medical needs and reducing healthcare costs. BSX’s medical products are well suited for an aging population, and the company’s stream of new inventions acquisitions add to promising growth prospects.
The recent acquisition of Apama Medical will expand BSX’s arrhythmia solutions which fall under its Electrophysiology (EP) segment. To further expand its EP segment, Boston Scientific announced plans to acquire Securus Medical, which is a developer of thermal monitoring systems for the continuous measurement of esophageal temperature.
Boston Scientific’s growth is bolstered by its expansion in emerging markets, including Brazil, Russia, India and China (BRIC). In the first-quarter, business from emerging markets grew by 17%.
Gray Cardiff, Sound Advice, www.soundadvice-newsletter.com, 800-825-7007, June 1, 2018